Apyx Medical's gross profit for the
three
months ended in Dec. 2024 was $8.96 Mil. Apyx Medical's gross profit for the trailing twelve months (TTM) ended in Dec. 2024 was $29.36 Mil.
Gross Margin % is calculated as gross profit divided by its revenue. Apyx Medical's gross profit for the
three
months ended in Dec. 2024 was $8.96 Mil. Apyx Medical's Revenue for the
three
months ended in Dec. 2024 was $14.22 Mil. Therefore, Apyx Medical's Gross Margin % for the quarter that ended in Dec. 2024 was 63.03%.
Apyx Medical had a gross margin of 63.03% for the quarter that ended in Dec. 2024 => Durable competitive advantage
During the past 13 years, the highestGross Margin % of Apyx Medical was 69.26%. The lowest was 42.54%. And the median was 64.85%.
Warning Sign:
Apyx Medical Corp gross margin has been in long-term decline. The average rate of decline per year is -1.4%.
Apyx Medical Gross Profit Historical Data
The historical data trend for Apyx Medical's Gross Profit can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Apyx Medical's Gross Profit
For the Medical Devices subindustry, Apyx Medical's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Apyx Medical's Gross Profit Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Apyx Medical's Gross Profit distribution charts can be found below:
* The bar in red indicates where Apyx Medical's Gross Profit falls into.
Gross Profit for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $29.36 Mil.
Gross Profit is the numerator in the calculation of Gross Margin.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Apyx Medical (NAS:APYX) Gross Profit Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Apyx Medical had a gross margin of 63.03% for the quarter that ended in Dec. 2024 => Durable competitive advantage
Apyx Medical Gross Profit Related Terms
Thank you for viewing the detailed overview of Apyx Medical's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.
Apyx Medical Corp is an energy technology medical device company. It specializes in developing, manufacturing, and marketing a range of cosmetic and surgical products and technologies, as well as related medical products used in doctor's offices, surgery centers, and hospitals. Its product offerings comprise Renuvion cosmetic technology, which offers plastic surgeons, facial plastic surgeons, and cosmetic physicians the ability to provide controlled heat to the tissue to achieve desired results. The J-Plasma system allows surgeons to operate with a high level of precision and virtually eliminates unintended tissue trauma. It operates in two segments namely: Advanced Energy and Original Equipment Manufacturing (OEM). Its Advanced Energy segment derives the majority of its revenue.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
APYX has been successfully added to your 